KUR 113

Drug Profile

KUR 113

Alternative Names: I-040202; KUR-113

Latest Information Update: 30 Jun 2016

Price : $50

At a glance

  • Originator Kuros Biosurgery
  • Developer Kuros Biosciences
  • Class Blood proteins; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Fracture

Most Recent Events

  • 30 Jun 2016 KUR 113 is available for licensing as of 28 Jun 2016. http://www.kuros.ch/
  • 15 Mar 2016 Biomarkers information updated
  • 19 Aug 2015 KUR 113 is still in phase II trials for Fracture in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top